133 related articles for article (PubMed ID: 19368954)
21. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse.
Rakozy CK; Mohamed AN; Vo TD; Khatib G; Long PM; Eilender D; Palutke M
Am J Clin Pathol; 2001 Aug; 116(2):168-76. PubMed ID: 11488062
[TBL] [Abstract][Full Text] [Related]
22. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
[TBL] [Abstract][Full Text] [Related]
23. Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases.
Sharara N; Holden JT; Wojno TH; Feinberg AS; Grossniklaus HE
Ophthalmology; 2003 Jun; 110(6):1245-54. PubMed ID: 12799255
[TBL] [Abstract][Full Text] [Related]
24. Clonal immunoglobulin gene rearrangements and normal T-cell receptor, bcl-2, and c-myc genes in primary cutaneous B-cell lymphomas.
Delia D; Borrello MG; Berti E; Pierotti MA; Biassoni D; Gianotti R; Alessi E; Rizzetti MG; Caputo R; Della Porta G
Cancer Res; 1989 Sep; 49(17):4901-5. PubMed ID: 2503246
[TBL] [Abstract][Full Text] [Related]
25. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.
Yao X; Teruya-Feldstein J; Raffeld M; Sorbara L; Jaffe ES
Mod Pathol; 2001 Feb; 14(2):105-10. PubMed ID: 11235901
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
27. Blastic NK-cell-like lymphoma with T-cell receptor gene rearrangement.
Liu XY; Atkins RC; Feusner JH; Rowland JM
Am J Hematol; 2004 Apr; 75(4):251-3. PubMed ID: 15054822
[TBL] [Abstract][Full Text] [Related]
28. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.
Jundt F; Acikgöz O; Kwon SH; Schwarzer R; Anagnostopoulos I; Wiesner B; Mathas S; Hummel M; Stein H; Reichardt HM; Dörken B
Leukemia; 2008 Aug; 22(8):1587-94. PubMed ID: 18449208
[TBL] [Abstract][Full Text] [Related]
30. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.
Picker LJ; Weiss LM; Medeiros LJ; Wood GS; Warnke RA
Am J Pathol; 1987 Jul; 128(1):181-201. PubMed ID: 3111266
[TBL] [Abstract][Full Text] [Related]
31. Reporter gene insertions reveal a strictly B lymphoid-specific expression pattern of Pax5 in support of its B cell identity function.
Fuxa M; Busslinger M
J Immunol; 2007 Jun; 178(12):8222-8. PubMed ID: 17600970
[TBL] [Abstract][Full Text] [Related]
32. The potential involvement of Notch signaling in NK cell development.
Rolink AG; Balciunaite G; Demolière C; Ceredig R
Immunol Lett; 2006 Sep; 107(1):50-7. PubMed ID: 16930724
[TBL] [Abstract][Full Text] [Related]
33. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas.
Chen W; Lau SK; Fong D; Wang J; Wang E; Arber DA; Weiss LM; Huang Q
Am J Surg Pathol; 2009 Jun; 33(6):863-73. PubMed ID: 19145200
[TBL] [Abstract][Full Text] [Related]
34. Reversion of B cell commitment upon loss of Pax5 expression.
Mikkola I; Heavey B; Horcher M; Busslinger M
Science; 2002 Jul; 297(5578):110-3. PubMed ID: 12098702
[TBL] [Abstract][Full Text] [Related]
35. Transient Notch signaling induces NK cell potential in Pax5-deficient pro-B cells.
Carotta S; Brady J; Wu L; Nutt SL
Eur J Immunol; 2006 Dec; 36(12):3294-304. PubMed ID: 17111353
[TBL] [Abstract][Full Text] [Related]
36. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5.
Nutt SL; Heavey B; Rolink AG; Busslinger M
Nature; 1999 Oct; 401(6753):556-62. PubMed ID: 10524622
[TBL] [Abstract][Full Text] [Related]
37. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease.
O'Brien P; Morin P; Ouellette RJ; Robichaud GA
Cancer Res; 2011 Dec; 71(24):7345-50. PubMed ID: 22127921
[TBL] [Abstract][Full Text] [Related]
38. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage.
Cattoretti G; Angelin-Duclos C; Shaknovich R; Zhou H; Wang D; Alobeid B
J Pathol; 2005 May; 206(1):76-86. PubMed ID: 15772984
[TBL] [Abstract][Full Text] [Related]
39. Isoforms of Pax5 and co-regulation of T- and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton's lymphoma.
Bharti B; Mishra R
Biochim Biophys Acta; 2011 Dec; 1813(12):2071-8. PubMed ID: 21854813
[TBL] [Abstract][Full Text] [Related]
40. The regulation of the B-cell gene expression programme by Pax5.
Holmes ML; Pridans C; Nutt SL
Immunol Cell Biol; 2008 Jan; 86(1):47-53. PubMed ID: 17998914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
